{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75"}]}],"title":"Linsitinib starting dose in milligrams"},{"categories":[{"measurements":[{"groupId":"OG000","value":"150"}]}],"title":"Linsitinib maximum dose in milligrams"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"* Phase 1: To determine the maximum tolerated dose (MTD) of ASP7487 (OSI-906) administered in combination with the recommended dose and schedule of bortezomib and dexamethasone;\n* Phase 2: To evaluate the antitumor activity of ASP7487 (OSI-906) in combination with bortezomib and dexamethasone at the MTD established from the Phase 1 component.","groups":[{"description":"ASP7487 administered orally 75, 100 and 150 mg) BID continuously for each cycle. Bortezomib administered at 1.3 mg/m2 twice weekly for the first 8 21 day cycles and once weekly beyond cycle 9 for 35 day cycles. Dexamethasone is administered on bortezomib administration days at 20 mg\n\nASP7487, Velcade, Dexamethasone: ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration","id":"OG000","title":"ASP7487, Velcade, Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"45 months","title":"Maximum Tolerated Dose of the Combination of ASP7487 (OSI-906) With Velcade and Dexamethasone","type":"PRIMARY","unitOfMeasure":"milligrams"}